Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma | Zendy

Alison J. Moskowitz | Zendy; Paul A. Hamlin | Zendy; MiguelAngel Perales | Zendy; John F. Gerecitano | Zendy; Steven M. Horwitz | Zendy; Matthew J. Matasar | Zendy; Ariela Noy | Zendy; Maria Lia Palomba | Zendy; Carol S. Portlock | Zendy; David J. Straus | Zendy; Tricia Graustein | Zendy; Andrew D. Zelenetz | Zendy; Craig H. Moskowitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma

Author(s) -

Alison J. Moskowitz,

Paul A. Hamlin,

MiguelAngel Perales,

John F. Gerecitano,

Steven M. Horwitz,

Matthew J. Matasar,

Ariela Noy,

Maria Lia Palomba,

Carol S. Portlock,

David J. Straus,

Tricia Graustein,

Andrew D. Zelenetz,

Craig H. Moskowitz

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.45.3308

Subject(s) - bendamustine , medicine , refractory (planetary science) , autologous stem cell transplantation , salvage therapy , transplantation , phases of clinical research , clinical endpoint , surgery , lymphoma , chemotherapy , clinical trial , rituximab , physics , astrobiology

Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research